<head>
    <!-- Stylesheet -->
    <link rel="stylesheet" href="css/safety.css">
</head>
<!-- Main -->
<main>
    <div class="tabs">
        <a href="" ui-sref="SAFETY" class="tab">SAFETY</a>
        <a href="" ui-sref="TOLERABILITY" class="tab tab--active">TOLERABILITY</a>
    </div>
    <h2 class="primary">
        Tolerability Established With the BELIEF Trial<sup>1,2</sup>
    </h2>
    <h3 class="secondary-variant">Most patients tolerated the target dose of BELEODAQ<sup>1,2</sup></h3>
    <div class="tolerability-data">
        <div class="data_figure">
            <h4 class="light">
                <span class="jumbo secondary">12<sup class="percent">%</sup></span>
                <span class="big secondary">OF PATIENTS</span>
                receiving BELEODAQ <span class="secondary semibold">required a dosage reduction</span> due to AEs
            </h4>
        </div>
        <img src="assets/svg/safety-graph.svg" alt="Most patients tolerated the target dose of BELEODAQ"/>
        <div class="data_figure">
            <h4 class="light">
                <span class="jumbo primary">88<sup class="percent">%</sup></span>
                <span class="big primary">OF PATIENTS</span>
                receiving BELEODAQ <span class="primary semibold">did not require a dosage reduction</span> due to AEs
            </h4>
        </div>
    </div>
    <div class="heartline">
        <img src="assets/svg/heartline-graphic.svg" alt="heartline graphic"/>
        <h4 class="secondary-variant2 semibold">In studies, BELEODAQ has not been associated with clinically relevant changes in heart rate or PR- or QRS-interval duration<sup>2</sup>
        </h4>
    </div>
    <div class="bounding_box">
        <h4 class="light">Dose reductions due to prolonged QTc or increased transaminases occurred in 2 of 129 patients<sup>1,2</sup></h4>
        <h4 class="light">Independent central review of ECG data identified these 2 patients with grade 3 QT prolongation and concluded that BELEODAQ had no effect on cardiac repolarization<sup>2</sup>
        </h4>
        <h4 class="light">Pharmacokinetic and pharmacodynamic analyses showed no correlation between BELEODAQ concentration and changes in QTc from baseline<sup>2</sup>
        </h4>
    </div>
    <h4 class="secondary-variant2 semibold">BELEODAQ is the only agent that the FDA has approved for the treatment of R/R PTCL that was studied in patients (N = 120) with platelet counts down to 50,000/μL<sup>2</sup></h4>
    <ul>
        <li>
            <h4 class="light">
            R/R PTCL patients with <span class="secondary-variant2 semibold">platelet counts &lt;100,000/μL</span> are typically <span class="secondary-variant2 semibold">ineligible for clinical trials<sup>10</sup></span>
            </h4>
        </li>
    </ul>
    <p class="light">AEs, adverse events; ECG, electrocardiogram; R/R PTCL, relapsed/refractory peripheral T-cell lymphoma.</p>
    <div class="button-group">
        <a href="" ui-sref="ORR" class="button secondary"><i class="fas fa-chevron-left"></i> Efficacy</a>
        <a href="" ui-sref="DOSING" class="button">Dosing &amp; Administration <i class="fas fa-chevron-right"></i></a>
    </div>
</main>